AI

FDA, OpenAI in Talks on AI Drug Review Amid Oversight Concerns

May 15, 2025
OpenAI has engaged in discussions with the U.S. Food and Drug Administration (FDA) regarding the agency’s efforts to expand its use of artificial intelligence (AI) to accelerate drug evaluations, amid broader plans to integrate AI more widely across its centers. OpenAI and the U.S. Food and Drug Administration have reportedly been in discussions over a
1 2 3 10